Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology
暂无分享,去创建一个
M. Scarpa | A. Dardis | A. Cifù | P. Rozenfeld | J. Mucci | F. Serra | E. Pavan | Dania Ferino | M. Ormazabal | E. Vaena | Jessica Biasizzo
[1] C. Mayhew,et al. iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology. , 2023, Molecular therapy. Methods & clinical development.
[2] M. Kumar,et al. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease , 2023, Human molecular genetics.
[3] E. Borgonovi,et al. High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study , 2023, Health services management research.
[4] D. Regier,et al. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone. , 2023, HealthcarePapers.
[5] A. Rubinacci,et al. Bone remodeling: an operational process ensuring survival and bone mechanical competence , 2022, Bone Research.
[6] A. Pession,et al. iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death , 2021, Cells.
[7] B. Bembi,et al. In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy , 2020, Molecular genetics and metabolism reports.
[8] J. Delaissé,et al. Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. , 2020, Bone.
[9] M. Niewada,et al. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years , 2020, Frontiers in Pharmacology.
[10] M. Delpino,et al. Unraveling the mystery of Gaucher bone density pathophysiology. , 2020, Molecular genetics and metabolism.
[11] H. Kitaura,et al. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption , 2020, International journal of molecular sciences.
[12] R. Feldman,et al. Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis. , 2020, Molecular genetics and metabolism.
[13] H. Das,et al. Transcriptional Regulation of Osteoclastogenesis: The Emerging Role of KLF2 , 2020, Frontiers in Immunology.
[14] A. Dardis,et al. CRISPR/Cas9 Editing for Gaucher Disease Modelling , 2020, International journal of molecular sciences.
[15] Friederike Zunke,et al. Modeling neuronopathic storage diseases with patient-derived culture systems , 2019, Neurobiology of Disease.
[16] L. Poll,et al. Gaucher Disease in Bone: From Pathophysiology to Practice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] M. Ormazábal,et al. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease , 2019, PloS one.
[18] A. Mehta,et al. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease. , 2018, Gene.
[19] Diana Miller,et al. Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition , 2018, Human molecular genetics.
[20] J. Sikora,et al. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II , 2018, Journal of Inherited Metabolic Disease.
[21] A. Wåhlin,et al. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. , 2018, Blood cells, molecules & diseases.
[22] F. Vairo,et al. Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1? , 2018, Blood cells, molecules & diseases.
[23] A. Schapira,et al. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons , 2018, Scientific Reports.
[24] D. Rigante,et al. Overview of immune abnormalities in lysosomal storage disorders. , 2017, Immunology letters.
[25] M. Plebani,et al. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS , 2017, Clinical chemistry and laboratory medicine.
[26] J. Stirnemann,et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.
[27] M. Delpino,et al. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease , 2017, International journal of molecular sciences.
[28] F. Zito,et al. The Alternative Faces of Macrophage Generate Osteoclasts , 2016, BioMed research international.
[29] P. Walther,et al. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca²⁺ release from acidic Ca²⁺ stores. , 2015, Cell calcium.
[30] J. Marugan,et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages , 2015, Aging cell.
[31] M. Delpino,et al. Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology. , 2015, Blood cells, molecules & diseases.
[32] R. Mignani,et al. Early markers of Fabry disease revealed by proteomics. , 2015, Molecular bioSystems.
[33] E. Sidransky,et al. New macrophage models of Gaucher disease offer new tools for drug development. , 2015, Macrophage.
[34] Ying Sun,et al. Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology , 2015, PloS one.
[35] Elias T. Zambidis,et al. Gaucher iPSC‐Derived Macrophages Produce Elevated Levels of Inflammatory Mediators and Serve as a New Platform for Therapeutic Development , 2014, Stem cells.
[36] A. Dutra,et al. Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs , 2014, Science Translational Medicine.
[37] A. Mehta,et al. Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. , 2013, Blood cells, molecules & diseases.
[38] R. Faccio,et al. The Interplay between the Bone and the Immune System , 2013, Clinical & developmental immunology.
[39] S. Teitelbaum,et al. Osteoclasts: New Insights , 2013, Bone Research.
[40] I. Biton,et al. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. , 2012, Brain : a journal of neurology.
[41] V. Vanneaux,et al. Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency. , 2012, Stem cells and development.
[42] Hongyu Zhao,et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage , 2010, Proceedings of the National Academy of Sciences.
[43] Liza J. Raggatt,et al. Cellular and Molecular Mechanisms of Bone Remodeling* , 2010, The Journal of Biological Chemistry.
[44] K. Matsuo,et al. The Mechanism of Osteoclast Differentiation Induced by IL-11 , 2009, The Journal of Immunology.
[45] M. Itzchaki,et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy , 2004, Acta orthopaedica Scandinavica.
[46] B. Bembi,et al. Gaucher’s disease with Parkinson’s disease , 2003, Neurology.
[47] J. Sussman,et al. X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.
[48] R. Dwek,et al. Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.
[49] V. Barak,et al. Cytokines in Gaucher's disease. , 1999, European cytokine network.
[50] C. Hollak,et al. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. , 1996, Biochimica et biophysica acta.
[51] 彭明珉. Gaucher病一例 , 1995 .
[52] Glucosylceramide modulates membrane traffic along the endocytic pathway , 2022 .